Anti-influenza Drugs Market 2028 By Product Type, Distribution Channel and Geography | The Insight Partners

Anti-influenza Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and Other Products); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others) and Geography

Report Code: TIPRE00025692 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-influenza Drugs - By Product type
1.3.2 Anti-influenza Drugs - By Distribution channel
1.3.3 Anti-influenza Drugs - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI-INFLUENZA DRUGS LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTI-INFLUENZA DRUGS - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTI-INFLUENZA DRUGS - GLOBAL MARKET ANALYSIS
6.1. ANTI-INFLUENZA DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI-INFLUENZA DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. ANTI-INFLUENZA DRUGS - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. PERAMIVIR
7.3.1. Overview
7.3.2. peramivir Market Forecast and Analysis
7.4. ZANAMIVIR
7.4.1. Overview
7.4.2. zanamivir Market Forecast and Analysis
7.5. OSELTAMIVIR PHOSPHATE
7.5.1. Overview
7.5.2. oseltamivir phosphate Market Forecast and Analysis
7.6. BALOXAVIR MARBOXIL
7.6.1. Overview
7.6.2. baloxavir marboxil Market Forecast and Analysis
7.7. OTHER PRODUCTS
7.7.1. Overview
7.7.2. other products Market Forecast and Analysis
8. ANTI-INFLUENZA DRUGS - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. RETAIL PHARMACIES
8.3.1. Overview
8.3.2. retail pharmacies Market Forecast and Analysis
8.4. HOSPITAL PHARMACIES
8.4.1. Overview
8.4.2. hospital pharmacies Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. others Market Forecast and Analysis
9. ANTI-INFLUENZA DRUGS REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Anti-influenza Drugs Overview
9.1.2 North America Anti-influenza Drugs Forecasts and Analysis
9.1.3 North America Anti-influenza Drugs Forecasts and Analysis - By Product type
9.1.4 North America Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.1.5 North America Anti-influenza Drugs Forecasts and Analysis - By Countries
9.1.5.1 United States Anti-influenza Drugs
9.1.5.1.1 United States Anti-influenza Drugs by Product type
9.1.5.1.2 United States Anti-influenza Drugs by Distribution channel
9.1.5.2 Canada Anti-influenza Drugs
9.1.5.2.1 Canada Anti-influenza Drugs by Product type
9.1.5.2.2 Canada Anti-influenza Drugs by Distribution channel
9.1.5.3 Mexico Anti-influenza Drugs
9.1.5.3.1 Mexico Anti-influenza Drugs by Product type
9.1.5.3.2 Mexico Anti-influenza Drugs by Distribution channel
9.2. EUROPE
9.2.1 Europe Anti-influenza Drugs Overview
9.2.2 Europe Anti-influenza Drugs Forecasts and Analysis
9.2.3 Europe Anti-influenza Drugs Forecasts and Analysis - By Product type
9.2.4 Europe Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.2.5 Europe Anti-influenza Drugs Forecasts and Analysis - By Countries
9.2.5.1 Germany Anti-influenza Drugs
9.2.5.1.1 Germany Anti-influenza Drugs by Product type
9.2.5.1.2 Germany Anti-influenza Drugs by Distribution channel
9.2.5.2 France Anti-influenza Drugs
9.2.5.2.1 France Anti-influenza Drugs by Product type
9.2.5.2.2 France Anti-influenza Drugs by Distribution channel
9.2.5.3 Italy Anti-influenza Drugs
9.2.5.3.1 Italy Anti-influenza Drugs by Product type
9.2.5.3.2 Italy Anti-influenza Drugs by Distribution channel
9.2.5.4 Spain Anti-influenza Drugs
9.2.5.4.1 Spain Anti-influenza Drugs by Product type
9.2.5.4.2 Spain Anti-influenza Drugs by Distribution channel
9.2.5.5 United Kingdom Anti-influenza Drugs
9.2.5.5.1 United Kingdom Anti-influenza Drugs by Product type
9.2.5.5.2 United Kingdom Anti-influenza Drugs by Distribution channel
9.2.5.6 Rest of Europe Anti-influenza Drugs
9.2.5.6.1 Rest of Europe Anti-influenza Drugs by Product type
9.2.5.6.2 Rest of Europe Anti-influenza Drugs by Distribution channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Anti-influenza Drugs Overview
9.3.2 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis
9.3.3 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis - By Product type
9.3.4 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.3.5 Asia-Pacific Anti-influenza Drugs Forecasts and Analysis - By Countries
9.3.5.1 Australia Anti-influenza Drugs
9.3.5.1.1 Australia Anti-influenza Drugs by Product type
9.3.5.1.2 Australia Anti-influenza Drugs by Distribution channel
9.3.5.2 China Anti-influenza Drugs
9.3.5.2.1 China Anti-influenza Drugs by Product type
9.3.5.2.2 China Anti-influenza Drugs by Distribution channel
9.3.5.3 India Anti-influenza Drugs
9.3.5.3.1 India Anti-influenza Drugs by Product type
9.3.5.3.2 India Anti-influenza Drugs by Distribution channel
9.3.5.4 Japan Anti-influenza Drugs
9.3.5.4.1 Japan Anti-influenza Drugs by Product type
9.3.5.4.2 Japan Anti-influenza Drugs by Distribution channel
9.3.5.5 South Korea Anti-influenza Drugs
9.3.5.5.1 South Korea Anti-influenza Drugs by Product type
9.3.5.5.2 South Korea Anti-influenza Drugs by Distribution channel
9.3.5.6 Rest of Asia-Pacific Anti-influenza Drugs
9.3.5.6.1 Rest of Asia-Pacific Anti-influenza Drugs by Product type
9.3.5.6.2 Rest of Asia-Pacific Anti-influenza Drugs by Distribution channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Anti-influenza Drugs Overview
9.4.2 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis
9.4.3 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis - By Product type
9.4.4 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.4.5 Middle East and Africa Anti-influenza Drugs Forecasts and Analysis - By Countries
9.4.5.1 South Africa Anti-influenza Drugs
9.4.5.1.1 South Africa Anti-influenza Drugs by Product type
9.4.5.1.2 South Africa Anti-influenza Drugs by Distribution channel
9.4.5.2 Saudi Arabia Anti-influenza Drugs
9.4.5.2.1 Saudi Arabia Anti-influenza Drugs by Product type
9.4.5.2.2 Saudi Arabia Anti-influenza Drugs by Distribution channel
9.4.5.3 U.A.E Anti-influenza Drugs
9.4.5.3.1 U.A.E Anti-influenza Drugs by Product type
9.4.5.3.2 U.A.E Anti-influenza Drugs by Distribution channel
9.4.5.4 Rest of Middle East and Africa Anti-influenza Drugs
9.4.5.4.1 Rest of Middle East and Africa Anti-influenza Drugs by Product type
9.4.5.4.2 Rest of Middle East and Africa Anti-influenza Drugs by Distribution channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Anti-influenza Drugs Overview
9.5.2 South and Central America Anti-influenza Drugs Forecasts and Analysis
9.5.3 South and Central America Anti-influenza Drugs Forecasts and Analysis - By Product type
9.5.4 South and Central America Anti-influenza Drugs Forecasts and Analysis - By Distribution channel
9.5.5 South and Central America Anti-influenza Drugs Forecasts and Analysis - By Countries
9.5.5.1 Brazil Anti-influenza Drugs
9.5.5.1.1 Brazil Anti-influenza Drugs by Product type
9.5.5.1.2 Brazil Anti-influenza Drugs by Distribution channel
9.5.5.2 Argentina Anti-influenza Drugs
9.5.5.2.1 Argentina Anti-influenza Drugs by Product type
9.5.5.2.2 Argentina Anti-influenza Drugs by Distribution channel
9.5.5.3 Rest of South and Central America Anti-influenza Drugs
9.5.5.3.1 Rest of South and Central America Anti-influenza Drugs by Product type
9.5.5.3.2 Rest of South and Central America Anti-influenza Drugs by Distribution channel
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANTI-INFLUENZA DRUGS
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ANTI-INFLUENZA DRUGS, KEY COMPANY PROFILES
12.1. ASTRAZENECA PLC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BIOCRYST PHARMACEUTICALS, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. DAIICHI SANKYO COMPANY, LIMITED.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. F. HOFFMANN-LA ROCHE LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MYLAN N.V.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NOVARTIS AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SANOFI
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SEQIRUS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

- AstraZeneca plc
- BIOCRYST PHARMACEUTICALS, INC.
- DAIICHI SANKYO COMPANY, LIMITED.
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc.
- Mylan N.V.
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Seqirus
TIPRE00025692
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount